Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Aims Lipid-lowering therapy (LLT) after acute coronary syndrome (ACS) typically follows stepwise intensification, delaying use of combination therapies and low-density lipoprotein cholesterol (LDL-C) goal attainment. We assessed whether access to a decision support system (DSS) altered the intensity of LLT prescribing vs. standard-of-care (SoC). Methods and results Pragmatic, multinational, parallel 1:1 cluster-randomized controlled trial of ACS patients comparing mandatory access to a DSS (providing estimates of cardiovascular events and benefits from different LLT scenarios) to SoC. The primary endpoint was the proportion receiving intensified monotherapy or initiated/escalated combination LLT by Week 16 compared to pre-admission LLT; secondary endpoints included individual components of the primary endpoint, proportions at goal (LDL-C < 1.4 mmol/L), and timing of LLT escalations. 42 sites from UK, Italy, and Spain were randomized, enrolling 1139 participants, 79% male, median age 62 years (IQR: 55, 69), 84% without prior CVD, 69% LLT-naïve at admission, and median admission LDL-C 3.0 mmol/L (IQR: 2.46, 3.75). The primary endpoint was met in 71.7% (DSS) vs. 65.7% (SoC) and risk ratio (RR) 1.11 (95%CI:0.92–1.33, P = 0.29). Intensification of monotherapy occurred in 9.0% vs. 13.1% (RR: 0.68, 95%CI: 0.46–1.00), combination LLT in 61.6% vs. 50.6% (RR: 1.35, 95%CI: 0.93–1.98). LDL-C goal achievement was 54.8% vs. 50.3% (RR 1.06, 95%CI: 0.88–1.28), with LLT escalation before discharge in 64.8% vs. 60.7%. Conclusion Access to a DSS, in hospitals managing ACS, did not improve LLT intensification within 16 weeks or LDL-C goal attainment but revealed a favourable trend towards earlier combination LLT use, which merits larger, longer studies in other settings.
Authors: Christophe A T Stevens, Jessica Smith, Julia Brandts, Fotios Barkas, Maria Moreno Morales, Leila Janani, Gaia Kiru, Nandita Kaza, Victoria Cornelius, Neil R Poulter, Kamlesh Khunti, John William McEvoy, Alberto Zambon, Jose L Lopez-sendon, Derek Connolly, Lorna Hazell, Kausik K Ray, the ZODIAC trial, Kausik K Ray, Victoria Cornelius, Neil R Poulter, Gaia Kiru, Leila Janani, Jessica Smith, Christophe A T Stevens, Maria Moreno Morales, Annie Wright, Eloise Britten, Felicia Frost, Francesco Lala, Jonathan Dao, Karen Danois, Lisa Feng, Lorna Hazell, Nandita Kaza, Nayan Das, Safa Anwar, Sima Toopchiani, Smita Das, Stephanie Amiridis, Vanaja Kakarla, Yasmin Abdat, Derek Connolly, Kamlesh Khunti, Vinoda Sharma, Christina Elorz, Andrew Moriarty, Afzar Zaman, Satheesh Balakrishnan-Nair, Rasha Al-Lamee, Azeem Sheikh, Mohamed Alama, George Hunter, David Ripley, Vivek Kodoth, Daniel McKenzie, Joe Martins, Rashed Hossain, Sharad Agrawal, Helen Routledge, Sukhbir Dhamrait, Alberto Zambon, Natale Brunetti, Alessandro Navazio, Gianni Casella, Paolo Calabrò, Giuseppe Andò, Claudio Fresco, Roberta Della Bona, Andrea Borin, Raffaele De Caterina, Alessandro Sciahbasi, Giuseppe Boriani, Jesús Peteiro, Jose Ramón González Juanatey, José Tuñón, Manuel Martínez Sellés, Leire Unzué, Carlos Arellano, Jose Lopez Aguilera, Alessandro Sionis, Roberto Martín, Raul Moreno, Alejandro Villanueva, Jordi Lozano, Domingo Pascual, Francisco Javier Cortés, Julia Brandts
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,725
Funder: Imperial College London
Award: G3853781647
OpenAlex ID: W4416425628
